Artwork

Content provided by Drug Science. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Drug Science or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

84. Will DMT be a medicine in the UK? with Dr Carol Routledge

55:26
 
Share
 

Manage episode 374399797 series 2528839
Content provided by Drug Science. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Drug Science or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Join us for an insightful episode featuring Dr. Carol Routledge, a distinguished senior scientist and the Chief Medical and Scientific Officer at Small Pharma Labs. Dr. Routledge takes us on a journey through her remarkable career path that ultimately led her to work at Small Pharma. With a wealth of experience in both preclinical and clinical settings, she has delved into psychiatric and neurological indications, honing her expertise in understanding and treating mental health disorders.

In this conversation, Dr. Carol Routledge draws upon her extensive clinical and psychedelic research background to shed light on the latest developments in DMT research and psychedelic integration therapy. With her profound insights, we explore the potential of these groundbreaking approaches to become formal medicines, revolutionizing the field of mental health treatment.

Tune in as Dr. Carol Routledge shares her passion for advancing mental health treatments through innovative research.

DMT

Depression

Serotonin

Nor adrenaline

Small Pharma

Chris Timmermann - Human brain effects of DMT assessed via EEG-fMRI

CMC

British technology group (BTG)

SSRI

Psychedelic experience

Alzheimers research uk

★ Support this podcast ★
  continue reading

136 episodes

Artwork
iconShare
 
Manage episode 374399797 series 2528839
Content provided by Drug Science. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Drug Science or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Join us for an insightful episode featuring Dr. Carol Routledge, a distinguished senior scientist and the Chief Medical and Scientific Officer at Small Pharma Labs. Dr. Routledge takes us on a journey through her remarkable career path that ultimately led her to work at Small Pharma. With a wealth of experience in both preclinical and clinical settings, she has delved into psychiatric and neurological indications, honing her expertise in understanding and treating mental health disorders.

In this conversation, Dr. Carol Routledge draws upon her extensive clinical and psychedelic research background to shed light on the latest developments in DMT research and psychedelic integration therapy. With her profound insights, we explore the potential of these groundbreaking approaches to become formal medicines, revolutionizing the field of mental health treatment.

Tune in as Dr. Carol Routledge shares her passion for advancing mental health treatments through innovative research.

DMT

Depression

Serotonin

Nor adrenaline

Small Pharma

Chris Timmermann - Human brain effects of DMT assessed via EEG-fMRI

CMC

British technology group (BTG)

SSRI

Psychedelic experience

Alzheimers research uk

★ Support this podcast ★
  continue reading

136 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide